News Briefing channel feed

PaxMed­ica surges af­ter fi­nanc­ing; Mar­i­nus makes Chi­na de­vel­op­ment and sales pact

3 years ago

Kriya ac­quires gene ther­a­py start­up for undis­closed sum; Com­pu­gen wins mile­stone pay­ment from As­traZeneca

3 years ago

El­e­vate­Bio and Affi­ni-T part­ner on KRAS ther­a­pies; Cas­ma rais­es $46M to drug the cell’s garbage dis­pos­al sys­tem

3 years ago

Sen­so­ri­on nabs rare pe­di­atric des­ig­na­tion for gene ther­a­py; Ava­lo sells off re­main­ing drug rights for $5M

3 years ago

San­thera lays out op­tions in bid for com­mer­cial­iza­tion funds; Swiss biotech’s Covid work nar­rows

3 years ago

Basilea’s can­cer pipeline slim­down con­tin­ues; Aque­s­tive looks to out­li­cense seizure drug in US

3 years ago

2sev­en­ty inks T cell part­ner­ship with Chi­nese biotech; An­ti­sense drug caus­es brain side ef­fect — re­port

3 years ago

Ever­est climbs clos­er to Covid-19 boost­er mar­ket; A French up­start snags funds to find drugs

3 years ago

Pfiz­er nabs eq­ui­ty stake in Swiss biotech work­ing on celi­ac ther­a­py; Verona gets more cash af­ter COPD win

3 years ago

Bio­Marin heads to FDA with he­mo­phil­ia A gene ther­a­py; Covid-fo­cused biotech signs a small SPAC deal

3 years ago

Mod­er­na gets Au­to­lus tar­get­ing tech via li­cens­ing deal; Atai re­ports PhI da­ta for kratom-based ther­a­py

3 years ago

Rigel steps back from sN­DA fil­ing plans for bleed­ing dis­or­der drug; NMD gives first look in­to myas­the­nia gravis pro­gram

3 years ago

Astel­las, Pan­th­er­na add or­gan to mR­NA tie-up; Rock­et launch­es sale of six fig­ures worth of stock

3 years ago
R&D

No­vo Nordisk touts an­oth­er once-week­ly in­sulin win; Mere­o's board bat­tle heats up again

3 years ago

Aim­ing for fourth nod, Sarep­ta files an­oth­er DMD gene ther­a­py to FDA; Ax­some head­ed to­ward mi­graine re­sub­mis­sion

3 years ago

Gami­da Cell prices its fol­low-on pub­lic of­fer­ing at $20M; Rally­bio touts Phase Ib da­ta for mon­o­clon­al an­ti­body

3 years ago

Seagen and Zai Lab ink part­ner­ship on Tiv­dak ex­pan­sion in­to Chi­na and sur­round­ing ar­eas; NC biotech snaps up seed fund­ing

3 years ago

Lipocine shifts fo­cus to CNS; Drug ap­proval trig­gers cap­i­tal in­fu­sion at Fen­nec

3 years ago

Pfiz­er and Sang­amo re-open PhI­II of he­mo­phil­ia A gene ther­a­py; AEON head­ed to PhI­II

3 years ago

Mer­ck and As­traZeneca get Lyn­parza OK in Chi­na for new in­di­ca­tion; BAR­DA ex­er­cis­es first op­tion with Mar­i­nus

3 years ago

Alpine eyes $100M cap­i­tal in­fu­sion; Bob Dug­gan lends $65M to cos­met­ics com­pa­ny-turned-biotech

3 years ago

Menar­i­ni Group and Sci­Clone Phar­ma­ceu­ti­cals ink deal to com­mer­cial­ize drug in Chi­na; Cel­sion to change its name

3 years ago

Re­jec­tion No. 2 for Medexus' decades-old chemo drug; Tre­vi touts chron­ic cough da­ta

3 years ago

Mallinck­rodt se­cures FDA ap­proval — but not with­out warn­ing; Rhythm seeks $100M af­ter reg­u­la­to­ry OKs

3 years ago
First page Previous page 19202122232425 Next page Last page
A service from the Financial Times